T. Rowe Price Associates
NAGE

T. Rowe Price Associates’s Niagen Bioscience NAGE Stock Holding History

T. Rowe Price Associates’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$312K Buy
97,521
+31,298
+47% +$127K ﹤0.01% 2838
2026
Q1 		$293K Buy
66,223
+5,881
+10% +$31.8K ﹤0.01% 2691
2025
Q4 		$384K Buy
60,342
+3,215
+6% +$22.4K ﹤0.01% 2515
2025
Q3 		$533K Buy
57,127
+2,382
+4% +$24.1K ﹤0.01% 2332
2025
Q2 		$789K Buy
54,745
+3,536
+7% +$34.9K ﹤0.01% 2089
2025
Q1 		$354K Sell
51,209
-6,095
-11% -$38.3K ﹤0.01% 2395
2024
Q4 		$304K Buy
57,304
+2,196
+4% +$12K ﹤0.01% 2505
2024
Q3 		$202K Hold
55,108
– – ﹤0.01% 2649
2024
Q2 		$151K Buy
55,108
+15,808
+40% +$52.9K ﹤0.01% 2666
2024
Q1 		$137K Hold
39,300
– – ﹤0.01% 2718
2023
Q4 		$57K Hold
39,300
– – ﹤0.01% 2792
2023
Q3 		$58K Hold
39,300
– – ﹤0.01% 2762
2023
Q2 		$62K Hold
39,300
– – ﹤0.01% 2776
2023
Q1 		$61K Hold
39,300
– – ﹤0.01% 2764
2022
Q4 		$66K Buy
39,300
+16,800
+75% +$26.6K ﹤0.01% 2778
2022
Q3 		$28K Hold
22,500
– – ﹤0.01% 2894
2022
Q2 		$38K Sell
22,500
-30,772
-58% -$60.2K ﹤0.01% 2890
2022
Q1 		$131K Buy
53,272
+17,600
+49% +$48.1K ﹤0.01% 2801
2021
Q4 		$133K Sell
35,672
-1,000
-3% -$5.4K ﹤0.01% 2829
2021
Q3 		$230K Buy
36,672
+11,281
+44% +$93K ﹤0.01% 2674
2021
Q2 		$250K Buy
25,391
+7,113
+39% +$62K ﹤0.01% 2645
2021
Q1 		$171K Sell
18,278
-9,916
-35% -$78.6K ﹤0.01% 2723
2020
Q4 		$135K Buy
28,194
+11,500
+69% +$56.1K ﹤0.01% 2603
2020
Q3 		$67K Buy
+16,694
New +$80.5K ﹤0.01% 2536

Other funds holding NAGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

T. Rowe Price Associates's NAGE Position: Q2 2026 in Review

T. Rowe Price Associates increased its Niagen Bioscience (NAGE) stake by 47% in Q2 2026, buying an estimated $127K and bringing the position to 97,521 shares worth $312K. The position accounts for ﹤0.01% of the portfolio, ranked #2838.

T. Rowe Price Associates first reported a position in NAGE in Q3 2020 and has held it in 24 quarters since. The position peaked at $789K in Q2 2025. 139 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.

  • T. Rowe Price Associates held 97,521 shares of Niagen Bioscience worth $312K as of Q2 2026.
  • T. Rowe Price Associates bought 31,298 Niagen Bioscience shares in Q2 2026, an estimated $127K.
  • Niagen Bioscience made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2838 holding.
  • T. Rowe Price Associates first reported a position in Niagen Bioscience in Q3 2020 and has held it in 24 quarters since.
  • T. Rowe Price Associates's Niagen Bioscience position peaked at $789K in Q2 2025.
  • 139 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.